Objective: Interleukin-18 (IL-18) has been recently demonstrated to improve experimental hyperphagia and insulin resistance. Paradoxically, concentrations of circulating IL-18 in obese subjects and in patients with type 2 diabetes are increased. The objective of this study is to provide an explanation for this paradox. Design: We have hypothesized that cells from obese individuals or from patients with type 2 diabetes mellitus have a diminished response to stimulation with IL-18. IL-18 responsiveness was tested by stimulating blood monocytes of obese or diabetes patients with rIL-18 or microbial components. Results: Obese individuals and patients with type 2 diabetes mellitus exhibit increased circulating concentrations of IL-18. More importantly, leukocytes isolated from obese or type 2 diabetes patients respond poorly after stimulation with IL-18, as reflected by defective interferon-g (IFNg) production. The defective response to IL-18 stimulation was accompanied by a 50% reduction in the expression of IL-18R a and b chains. In addition, cells of patients with obesity and diabetes displayed an impaired release of IFNg after challenge with bacterial or fungal pathogens, which was due to defective IL-18-mediated signaling. Conclusion: Patients with obesity or type 2 diabetes mellitus are characterized by lower responses after stimulation with IL-18. This IL-18 resistance explains the association of obesity and diabetes with high IL-18 circulating concentrations, similar to hyperinsulinemia and hyperleptinemia. IL-18 resistance may represent an important mechanism of the increased susceptibility of these patients to a number of infections.
Introduction
Interleukin-18 (IL-18) is a proinflammatory cytokine that belongs to the IL-1 cytokine family, because of its structure, receptor family and signal transduction pathways.
1 IL-18 has initially been described as interferon-g (IFNg)-inducing factor, due to its strong effects on stimulating IFNg release in the presence of co-stimuli such as IL-12 or lipopolysaccharide (LPS). 2 IL-18 is produced as an inactive precursor by macrophages, monocytes, dendritic cells, osteoblastic stroma cells and cells of the central nervous system, and it requires cleavage by caspase-1 to release the active peptide. 3 Decreased IFNg production is the hallmark of mice deficient in either IL-18, IL-18 receptor or caspase-1. 4 Several studies have shown elevated circulating IL-18 concentrations in subjects with obesity and insulin resistance, [5] [6] [7] [8] [9] and a recent study has demonstrated that a common IL-18 haplotype is associated with a higher body mass index in patients with type 2 diabetes or coronary heart disease. 10 In addition, weight loss after bariatric surgery results in the diminishing of IL-18 concentrations in the blood. 11 Using genetically modified mice, we have recently
shown that absence of IL-18 results in hyperphagia, obesity and insulin resistance, and that administration of recombinant IL-18 corrects these defects. 12 Our data were confirmed and complemented by a study showing that IL-18 controls energy homeostasis by suppressing appetite and feed efficiency. 13 A hypothesis to reconcile these clinical and experimental data is that subjects with obesity and insulin resistance have higher circulating concentrations of IL-18 because they are less responsive (resistant) to IL-18. Such an IL-18 resistance may exist toward its metabolic effects, but may also be present at the level of the immunological actions of IL-18. Indirect epidemiological evidence suggests that IL-18 hyporesponsiveness may be indeed present in these groups of patients. Although more extensively studied in patients with diabetes, both individuals with obesity and those with type 2 diabetes mellitus have an increased susceptibility to infections compared with healthy individuals. [14] [15] [16] A strong association between diabetes mellitus and susceptibility to tuberculosis has been reported almost a century ago, and validated by recent studies. 17, 18 Several explanations have been proposed for the increased susceptibility to infections in these patients, such as the facilitation of bacterial growth by hyperglycemia, negative effects of ketoacidosis on the function of the leukocytes, and also a disturbed activation of cellular and/or humoral immunity due to impaired production of proinflammatory cytokines. [19] [20] [21] [22] The latter has been supported by multiple studies reporting a defective production of proinflammatory Th1-type cytokines, such as IFNg. IFNg activates phagocytosis, stimulates the release of oxygen and nitrogen radicals by neutrophils and macrophages and increases intracellular bacterial killing, 23 and these mechanisms have been suggested to be affected in patients with obesity or diabetes. 14 Although the defective release of Th1 cytokines has been proposed both in obesity 24 and type 2 diabetes mellitus, 25, 26 the proximal molecular mechanism responsible for this effect remains elusive. As detailed above, IFNg production is under strong regulation by IL-18, and it may be speculated that the defective IFNg production in these conditions may be related to decreased responses to the effects of IL-18.
In this study, we tested the hypothesis that cells isolated from obese subjects or diabetes patients are resistant to the effects of IL-18.
Methods

Patients
Seventeen lean nondiabetic individuals (9 men/8 women, age 50.2±13.6 years, BMI 22.6±2.8 kg/m 2 ), 11 obese nondiabetic individuals (6 men/5 women, age 52.2±11.0 years, BMI 33.3 ± 3.9 kg/m 2 ) and 14 age-and weight-matched patients with type 2 diabetes mellitus (8 men/6 women, age 56.9±13.1 years, duration of the disease 8.3±5.9 years, BMI 31.6 ± 4.7 kg/m 2 ) participated in the study. None of the lean or obese individuals were treated with pharmacological agents at the time of the study. Eight of the type 2 diabetes patients were treated with insulin therapy, and the other six with sulfonylurea derivates and/or metformin. None of these medications have been shown to modulate IFNg production. An elevated C-reactive protein (CRP) measurement (415 mg l À1 ) was an exclusion criterion for the study, and none of the patients or controls had any infectious or autoimmune diseases at the time or the study. CRP measurements were below 15 mg l À1 in all volunteers, and below detection limit in all lean volunteers, eight of the obese volunteers and seven of the type 2 diabetes patients. Insulin sensitivity in obese vs lean subjects was assessed by the homeostasis model assessment of insulin resistance (HOMA) index and euglycemic hyperinsulinemic clamps. Compared with lean subjects, the group of obese subjects was insulin resistant as reflected by higher HOMA and lower glucose infusion rates, as presented in Table 1 . . The reversible caspase-1 inhibitor was diluted to the desired concentration in RPMI. All reagents used were endotoxin free, as tested in a lymulus amoebocyte lysate (LAL) assay.
Reagents
Isolation of peripheral blood mononuclear cells and cytokine stimulation Venous blood was drawn from the cubital vein into EDTA tubes (Monoject, s-Hertogenbosch, Netherlands). Peripheral blood mononuclear cells (PBMCs) were isolated by density ). Secondly, PBMCs were stimulated with the IL-18 in the presence of LPS (10 ng ml À1 ), which is known to amplify the IL-18-induced IFNg production.
The cytokine production induced by microbial pathogens was assessed after stimulation of 5 Â 10 5 mononuclear cells (in 100 ml of medium) with 100 ml heat-killed (30 min, 100 1C) Staphylococcus aureus (clinical strain isolated from patient with skin abcess, 1 Â 10 7 ml
À1
) or Candida albicans (ATCC MYA-3573, 1 Â 10 7 ml
). After 24 h and 48 h of incubation at 37 1C, supernatants were collected and stored at À80 1C until cytokines were measured. The role of IL-18 for the induction of cytokines by microbial stimuli was explored by blocking endogenous IL-18 effects with IL-18BP during stimulation. The viability of the cells has been tested by Tripan-blue exclusion method and was above 95% in all experimental conditions tested.
Cytokine measurements IL-18 concentrations were measured by a specific enzymelinked immunosorbent assay (ELISA) (Medical and Biological Laboratories, Nagoya, Japan), with a lower detection limit of 12.5 pg ml
. Tumor necrosis factor-a (TNFa) concentrations (detection limit 20 pg ml
) were determined by a specific ELISA.
27 IL-6 (detection limit 20 pg ml
) and IFNg (detection limit 4 pg ml À1 ) concentrations were measured by commercial ELISA kits (Pelikine Compact, Sanquin, Amsterdam, The Netherlands), according to the instructions of the manufacturer. Intraassay variation of the methods was less than 10%, and the interassay variation was lower than 15%.
Quantitative PCR analysis of IL-18 receptor (IL-18R)a and IL-18Rb
Peripheral blood mononuclear cells were isolated from the blood of the patients as described above. The cells were resuspended in 200 ml RNAzolB isolation solvent (Campro Scientific, Berlin, Germany) and frozen at À80 1C for storage. mRNA was isolated following the manufacturer's protocol. The amount and quality of mRNA were determined by spectrophotometry and analyzed by agarose gel electophoresis for DNA contamination. cDNA was synthesized from 1000 ng of total RNA using SuperScript Reverse Transcriptase (Invitrogen Corp., Carlsbad, CA, USA; 18064-014). Subsequently, quantitative PCR was performed using ABI/PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). PCRs were performed with Sybr Green PCR Master Mix (Applied Biosystems), 5 ml 1/20 diluted cDNA and primers in a final concentration of 300 nmol l À1 in a total volume of 25 ml. 
Results
Circulating IL-18 concentrations in lean, obese and diabetic individuals The general clinical and laboratory characteristics of the three groups are presented in Table 1 . The fasting serum IL-18 concentration was the highest in the type 2 diabetes patients: 438.3±49.5 pg ml À1 . In the obese individuals, fasting serum IL-18 concentrations were 360.6 ± 36.5 pg ml
À1
, and in the lean volunteers 303.9 ± 37.3 pg ml À1 (Figure 1 ). ). However, no significant correlations were found between IL-6 and IL-18 concentrations, suggesting an independent regulation of their production.
PBMCs from obese and diabetic individuals release low amounts of IFNg in response to IL-18 Interferon-g concentrations released were below detection limit of the assay when low concentrations of IL-18 (0.1 and 1 ng ml À1 ) were used for stimulation of PBMCs (not shown). When stimulated with 10 ng ml À1 of IL-18, PBMCs from obese and diabetic individuals released significantly lower amounts of IFNg than cells of lean individuals (Figure 2a) . To explore the mechanisms responsible for the reduced IFNg response to IL-18 in obese and diabetic individuals, the expression of the IL-18 receptor (IL-18R)a and IL-18Rb mRNA was assessed by quantitative real-time PCR. As shown in Figure 2b , the expression of IL-18Ra was approximately 50% lower in both obese and diabetic individuals compared with lean individuals (Po0.03 for obese vs lean, and Po0.02 for diabetes vs lean individuals, Figure 2b ). In contrast, IL-18Rb was significantly reduced in diabetic patients only, although a trend toward lower expression levels was also apparent in obese individuals (Figure 2b) .
Lipopolysaccharide strongly synergized with recombinant IL-18 for the production of IFNg, as shown in Figure 2c . However, when stimulated with a combination of LPS and IL-18, cells of obese and diabetic individuals also released significantly less IFNg compared with lean controls (Figure 2c) . It is important to observe that IFNg production was more severely affected in patients with type 2 diabetes than in nondiabetic obese individuals (Figure 2a and C) . In contrast to its induction of IFNg, IL-18 by itself induced low amounts of TNFa, and only additive effects between LPS and IL-18 were observed. No differences between TNFa production by PBMCs isolated from the three groups of individuals were apparent (Figure 2d ).
Decreased IFNg production in response to S. aureus or C. albicans in patients with type 2 diabetes mellitus We investigated whether individuals with diabetes or obesity have a disturbed cytokine production induced by these microorganisms, and whether this is mediated by a diminished response to endogenous IL-18. Patients with diabetes, IL-18 resistance, obesity and diabetes GRC Zilverschoon et al but not with obesity alone, had a significantly lower IFNg production in response to S. aureus or C. albicans than lean or obese control individuals ( Figure 3a) . As expected, production of TNFa and IL-6, which are not IL-18 dependent, did not differ between the three groups (Figure 3b and c) .
The role of endogenous IL-18 in the production of IFNg in diabetic patients
To investigate whether the defective IFNg production in patients with diabetes is due to intermediary production of IL-18, we blocked the production of IL-18 with the caspase-1 inhibitor Ac-Tyr-Val-Ala-Asp-2,6-dimethylbezoyloxymethylketone, and we used IL-18 binding protein (IL-18BP) to neutralize IL-18. Both caspase-1 inhibition or addition of IL-18BP strongly inhibited IFNg production induced by S. aureus or C. albicans (Figure 4) . When the IL-18 pathway was blocked by either of these methods, no differences of IFNg production were observed between diabetic, obese and lean individuals (Figure 4) , demonstrating that the differences in IFNg synthesis during microbial stimulation of cells from diabetes patients and lean individuals are mediated by an IL-18-dependent pathway. In contrast to IFNg production, the release of TNFa (Figure 4 ) and IL-6 (not shown) induced by the microbial stimuli was not influenced by either caspase-1 inhibition or IL-18BP blockade of endogenous IL-18.
Discussion
In this study, we tested the hypothesis that obese subjects and patients with type 2 diabetes are resistant to the effects of IL-18. The sensitivity of host cells to IL-18 was assessed by stimulating cells from lean subjects, obese individuals and diabetes patients, with IL-18, alone or in combination with LPS as an amplifying signal. Under either stimulatory condition, patients with obesity or diabetes produced significantly less IFNg in response to IL-18 stimulation. This defect was apparent even while the group of obese individuals showed a tendency toward higher IL-18 circulating concentrations, and patients with diabetes mellitus had significantly higher circulating levels of IL-18. Subsequently, the severity of this defect was greater in patients with diabetes than in obese individuals. From this point of view, IL-18 sensitivity decreases (and thus IL-18-resistance increases) from lean individuals without insulin resistance, to obese subjects who are insulin resistant, to BMI-matched individuals with overt type 2 diabetes. Production of IFNg by lymphocytes is under the control of the intermediary action of endogenous IL-18 and IL-12 produced by monocytes. IL-18 is particularly important in this respect, with IL-12 or exogenous microbial stimuli providing an amplifying signal by increasing IL-18R expression. 28 Although only a trend in our study, several studies have reported the presence of increased concentrations of IL-18 in the circulation of patients with obesity, and reversal toward normal concentrations after weight loss. [5] [6] [7] [8] [9] Considering the immune effects of IL-18 (that is, stimulation of IFNg production), the increased IL-18 concentrations combined with low IFNg production as shown here appear paradoxical. As an explanation, we provide evidence that cells from diabetic patients have an impaired responsiveness to the effects of IL-18. The IL-18 resistance observed would also explain why the anorexigenic and hypoglycemic effects of IL-18, which were recently reported by us and others, 12, 13 do not correct the obesity and insulin resistance in obese IL-18 resistance, obesity and diabetes GRC Zilverschoon et al individuals and diabetes patients with high IL-18 plasma concentrations.
Our data point to the IL-18 receptor as the molecular site responsible for the observed IL-18 resistance. Obesity and diabetes are characterized by resistance to the metabolic effects of insulin ('insulin resistance'), and recent studies have suggested similar low responsiveness to the effects of leptin ('leptin resistance'). These defects have been proposed to be largely regulated at the level of post-receptor signaling pathways. 29, 30 Although the IL-18 resistance reported in this study is an immunological phenomenon, a tempting hypothesis (that remains to be demonstrated) is that a similar resistance to the metabolic effects of IL-18 is also present. Because the low expression of IL-18 receptors on human leukocytes precludes the reliable assessment of the molecules by flow cytometry, we assessed the mRNA expression of IL-18Ra and b by quantitative real-time PCR. The expression of both receptor chains was lower in patients with diabetes compared with lean healthy individuals, whereas obese subjects have a significantly reduced expression of IL-18Rb mRNA. The greater decrease in expression of IL-18Rs in diabetes patients as compared with the obese individuals may explain the more pronounced phenotype of the former group in terms of suppressed IFNg responses and their enhanced susceptibility to infection. However, additional mechanisms of IL-18 resistance may very well be involved, including defective activation of its receptor pathways. In this respect, it is relevant to mention that one of the intracellular pathways activated by IL-18R, STAT3 phosphorylation, is also crucial for the insulin and leptin resistance, 31 and, as we have shown, responsible for the obesity and insulin resistance in IL-18À/À mice. 32 This also explains the selective deficiency of IFNg production in obese and diabetes subjects upon stimulation with IL-18: the induction of IFNg by IL-18 involves mitogen-activated protein kinase 33 and signal transducer and activator of transcription 3 (STAT-3), 34 whereas production of TNF and IL-6 are nuclear factor-kB-mediated events. 35, 36 The observed resistance to the effects of IL-18 may not only be important for the energy and glucose metabolism, 12 but could also explain theFalready mentionedFincreased susceptibility to infections in obese individuals and patients with diabetes. Many common infections have been shown to be more frequent in patients with diabetes, including community-acquired pneumonia, urinary tract infection and soft-tissue infection. [37] [38] [39] Similar to the patients with diabetes, obese individuals have been reported to display an increased susceptibility to the same types of common infection. 15 Because central obesity, insulin resistance and diabetes are components of the metabolic syndrome, one may speculate that similar pathophysiological mechanisms are responsible for the increased susceptibility to infections in both these two clinical conditions. Several mechanisms of host defense have been described to contribute to the susceptibility to infections of patients with diabetes mellitus. Adherence, chemotaxis, phagocytosis and microbicidal IL-18 resistance, obesity and diabetes GRC Zilverschoon et al activity of leukocytes have all been proposed to be impaired in patients with diabetes, as is T-cell-dependent cellular immunity. [19] [20] [21] [22] Interestingly, all cellular immune processes that are defective in diabetes are under the control of proinflammatory cytokines, with special emphasis on IFNg.
Interferon-g is a cytokine secreted by natural killer (NK) and T-helper 1 (Th 1 )-type lymphocytes, and its production has been reported to be impaired in both diabetic 25, 26 and obese 24 individuals. The pathophysiological mechanism responsible for the defective IFNg production in these disorders is not known. We investigated the mechanism of decreased IFNg production in diabetes patients after stimulation of their cells with two microorganisms (S. aureus and C. albicans) known to frequently cause infections in this type of patients. By using two approaches to block the function of endogenous IL-18 (caspase-1 inhibition and use of IL-18BP), we demonstrate that the IFNg production defect in diabetes patients after stimulation with pathogenic microorganisms is dependent on endogenous IL-18. In the absence of active IL-18, the IFNg production was no longer different between lean subjects, obese individuals and patients with diabetes. Therefore, we propose that the impaired IFNg response of leukocytes in response to IL-18 is a common pathway of increased susceptibility to infections in obese individuals and patients with diabetes.
In conclusion, this study is the first to present an explanation for the defective IFNg production by leukocytes isolated from obese individuals or patients with type 2 diabetes. We propose that IL-18-resistance is the underlying defect behind the diminished IFNg production and impaired cellular immunity in these patients. Considering the recent reports of a beneficial role of IL-18 on the energy and glucose metabolism, one may speculate whether IL-18 resistance in patients with type 2 diabetes and obese subjects is an isolated defect of the immune function of these patients, or, more likely, is a general mechanism with broad implications for both host defense and metabolic homeostasis.
